Photo-neutron cross-section of 100Mo

Crasta, Rita; Naik, H.; Suryanarayana, S. V.; Prajapati, P. M.; Jagadisan, K. C.; Thakare, S. V.; Sanjeev, Ganesh; Nimje, V.T.; Mittal, K.C.; Goswami, A.

doi:10.1007/s10967-011-1247-z

Cited by 23 publications

(14 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nuclear data for some reactions are known [cf. [11][12][13] with reasonable accuracy for present calculations. Today, the most promising route is the 100 Mo(p,2n) 99m Tc reaction using highly enriched target material.…”

Section: Diagnostic Radionuclidessupporting

confidence: 67%

Nuclear data for medical applications: An overview of present status and future needs

Syed

2017

EPJ Web Conf.

View full text Add to dashboard Cite

Abstract.A brief overview of nuclear data required for medical applications is given. The major emphasis is on radionuclides for internal applications, both for diagnosis and therapy. The status of the presently available data is discussed and some of the emerging needs are outlined. Most of the needs are associated with the development of non-standard positron emitters and novel therapeutic radionuclides. Some new developments in application of radionuclides, e.g. theranostic approach, multimode imaging, radionanoparticles, etc. are described and the related nuclear data needs are discussed. The possible use of newer irradiation technologies for medical radionuclide production, e.g. intermediate energy charged-particle accelerators, high-power electron accelerators for photon production, and spallation neutron sources, will place heavy demands on nuclear data.

show abstract

Section: Diagnostic Radionuclidessupporting

confidence: 67%

Nuclear data for medical applications: An overview of present status and future needs

Syed

2017

EPJ Web Conf.

View full text Add to dashboard Cite

show abstract

“…The cross section of the 100 Mo(γ, n) 99 Mo reaction is also small (150 mb at the maximum of the peak at 14 MeV) [cf . 100].…”

Section: Mo and 99m Tcmentioning

confidence: 99%

“…100]. A study on the 100 Mo(n, 2n) 99 Mo process [cf . 101] claims that amounts of 99 Mo comparable to those produced through the 98 Mo(n, γ ) 99 Mo reaction in a low flux reactor could be obtained, provided a proper accelerator for 14 MeV neutron production (through the d, t reaction) is developed.…”

Section: Mo and 99m Tcmentioning

confidence: 99%

“…The technical difficulties to be overcome are enormous; furthermore, the drawbacks of the 99 Mo produced with large amount of the inactive carrier will remain (see discussion above). More attention is therefore presently focused on production of 99 Mo and 99m Tc using charged-particle induced reactions on 100 Mo. The possibility of production of 99 Mo through the 100 Mo( p, d + pn) 99 Mo reaction was investigated under an IAEA-sponsored project, utilizing highly enriched 100 Mo target [cf .…”

Section: Mo and 99m Tcmentioning

confidence: 99%

“…More attention is therefore presently focused on production of 99 Mo and 99m Tc using charged-particle induced reactions on 100 Mo. The possibility of production of 99 Mo through the 100 Mo( p, d + pn) 99 Mo reaction was investigated under an IAEA-sponsored project, utilizing highly enriched 100 Mo target [cf . 102]; due to low cross section it was found to be unsuitable.…”

Section: Mo and 99m Tcmentioning

confidence: 99%

See 2 more Smart Citations

The present and future of medical radionuclide production

Qaim

2012

Radiochimica Acta

100

View full text Add to dashboard Cite

Reactor and cyclotron production of medical radionuclides / γ -ray emitters for SPECT / Positron emitters for PET / Corpuscular radiation emitters for internal radiotherapy / Low and intermediate energy nuclear reactions / Radionuclide generators / Future directionsSummary. Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68 Ga and 99m Tc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.

show abstract